Hepatitis C and hepatitis B-related mortality in Spain

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 8, 2009, Pages 895-901

  García Fulgueiras, Ana ^a,b,e   García Pina, Rocío ^a,b   Morant, Consuelo ^c   García Ortuzar, Visitación ^a,b   Génova, Ricard ^c   Alvarez, Elena ^d  

^a DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Regional Health Council   (Spain)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Burden of disease; Cirrhosis; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Mortality; Years of life lost

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC HEPATITIS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; INFANT; INTERNATIONAL CLASSIFICATION OF DISEASES; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; PRIORITY JOURNAL; SPAIN; AGE DISTRIBUTION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER NEOPLASMS; MIDDLE AGED; PRESCHOOL CHILD; SEX RATIO; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INFANT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SEX DISTRIBUTION; SPAIN; YOUNG ADULT;

EID: 67651064732     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328313139d     Document Type: Article

References (59)

1. Doré GJ, Freeman AJ, Law M, Kaldor MK. Natural history models for hepatitis-C related liver disease: different disease progression parameters for different settings. Antivir Ther 2003; 8:365-372. (Pubitemid 37351553)
2. EASL. International consensus conference on hepatitis B. J Hepatol 2003; 38:533-540.
3. Wiesner RH, Sorrell M, Villamil F, and the International Liver Transplantion Society Expert Panel. Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C. Liver Transpl 2003; 9 (11 Suppl 3):S1-S9.
4. Pietro M, Aguilera V, Berenguer M, Rubín A, Benlloch S, Aguas M. Actualización del trasplante hepático en la hepatitis C. Gastroenterol Hepatol 2007; 30 (Suppl 1):62-69.
5. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000; 14:703-709.
6. Seef LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006; 25:3771-3777.
7. The Global Burden of Hepatitis CWorking Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004; 44:20-29.
8. Mathers CD, Stein C, Ma Fat D, Rao C, Inoue M, Tomijima N, et al. Global burden of disease 2000: version 2 methods and results. Global Programme on Evidence for Health Policy Discussion Paper No. 50. Geneva: World Health Organization; 2002. Available at: http://www.who.int/healthinfo/paper50.pdf.
9. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Tenth revision. Geneva: World Health Organization; 1992.
10. Instituto Nacional de Estadística. Manual de Causas de Defunción (CIE-10). Versiones 2 a 7.1. Madrid: INE; 1999-2007.
11. National Statistics Institute. Spanish Statistical Office. Deaths by cause of death, 2000. Madrid; Available at: www. ine.es/inebmenu/mnu-salud.htm.
12. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
13. Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 (global burden of disease and injury series; I). Cambridge (Massachusetts): Harvard University Press; 1996.
14. Álvarez E, Génova R, Morant C, Freire JM. Burden of disease estimate in Spain in 2000 [in Spanish]. Gac Sanit 2004; 18:36.
15. Gesmor: Software to calculation disability adjusted life years developed by the Carlos III Institute of Public Health (Madrid). Supported by the Health Mexican Foundation (FUNSALUD) and the Interamerican Bank for Development. Available at http://www. funsalud.org.mx/red-jlb/gesmor.htm.
16. Bréchot Ch, Jaffredo F, Lagorce D, Gerken G, Meyer K, Papakonstontinou A, et al. Impact of HBV, HCV and GBV-C/HGV on HCC in Europe; results of a European concerted action. J Hepatol 1998; 29:173-182.
17. Bosch FX , Rives J, Cléries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9:191-211.
18. García-Torres ML, Zaragozá A, Giner R, Primo J, del Olmo JA. Incidence and epidemiological factors of hepatocellular carcinoma in Valencia during the year 2000. Rev Esp Enferm Dig 2003; 95:381-384.
19. Macías MA, Rendón P, Tejada M, Infante JM, Correro F, Díaz F, et al. Risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Rev Esp Enferm Dig 2000; 92:464-469.
20. Crespo J, Dueñas C, Sánchez-Antolín G, Fábrega E, Carte B, Pons-Romero F. Hepatitis B and C virus infection in patients with hepatocellular carcinoma. Med Clin (Barc) 1996; 106:241-245. (Pubitemid 126594750)
21. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; II:1004-1006. (Pubitemid 19257915)
22. Stroffolini T. Etiological factor of hepatocellular carcinoma in Italy. Minerva Gastroenterol Dietol 2005; 51:1-5. (Pubitemid 44251914)
23. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in Cirrhosis: incidence and risk factors. Gastroenterology 2004; 127:S35-S50. (Pubitemid 39423368)
24. Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006; 15:683-689.
25. Del Olmo JA, Serra MA, Rodriguez F, Escudero A, Gilabert S, Rodrigo JM. Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. J Cancer Res Clin Oncol 1998; 124:560-564. (Pubitemid 28513119)
26. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29:1596-1601. (Pubitemid 29211066)
27. Sagmeister M, Renner EL, Mullhaupt B, Wong JB. Simulation of hepatitis C based on a mandatory reported system. Eur J Gastrol Hepatol 2002; 14:25-34. (Pubitemid 34112158)
28. Raptis I, Koskinas J, Emmanouil T, Hadziyannis S. Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations. J Viral Hepatitis 2003; 10:450-454. (Pubitemid 37352587)
29. Management of hepatitis C: 2002. NIH Consens State Science Statements. 2002 June 10-12; 19:1-46.
30. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569. (Pubitemid 30729201)
31. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53:744-749. (Pubitemid 38561455)
32. Martín-Carbonero L, Sánchez-Somolinos M, García-Samaniego J, Nuñez MJ, Valencia ME, González-Lahoz J, et al. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. J Viral Hepatitis 2006; 13:851-857. (Pubitemid 44748291)
33. Santín Cerezales M. Hepatitis C crónica en pacientes con infección por el VIH: algunas evidencias y algunas preguntas por responder. AIDS Cyber J 2002; 5:35-40.
34. Miró JM, Montejo M, Rufi G, Bárcena R, Vargas V, Rimola A, et al. Liver transplantation in patients with HIV infection: a reality in 2004. Enferm Infecc Microbiol Clin 2004; 22:529-538.
35. Macias J, Melguizo I, Fernández-Rivera FJ, Garcia-García A, Mira JA, Ramos AJ, et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Inf ect Dis 2002; 21:775-781. (Pubitemid 35435698)
36. Quintana M, Del Amo J, Barrasa A, Pérez-Hoyos S, Ferreros I, Hernandez F, et al. Progression of HIV infection and mortality by hepatitis C infection in patients with haemophilia over 20 years. Haemophilia 2003; 9:605-612. (Pubitemid 37236098)
37. Del Amo J, Perez-Hoyos S, Moreno A, Quintana M, Ruiz I, Cisneros JM, et al. Trends in AIDS and mortality in HIV-infected subjects with hemophilia from 1985 to 2003. The competing risks for death between AIDS and liver disease. J Acquir Immune Defic Syndr 2006; 41:624-631.
38. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al; for the EuroSIDA study group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
39. Lewden CH, Salmon D, Morlat PH, Bévilacqua S, Jougla E, Bonnet F, et al. Causes of death among HIV infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-130.
40. Monga HK, Rodriguez-Barradas MC, Breaux K, Troisi CL, Velez M, Yoffe B. Hepatitis C virus infection-related morbidity and mortality among patients with HIV infection. Clin Infect Dis 2001; 33:240-247.
41. Louie JK, Chin Hsu L, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002; 186:1023-1027.
42. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama CH, et al; for the EuroSIDA group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Acquir Immune Defic Syndr 2005; 19:593-601.
43. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
44. Palmateer NE, Hutchinson SJ, McLeod A, Codere G, Goldberg DJ. Comparison of deaths related to hepatitis C and AIDS in Scotland. J Viral Hepat 2007; 14:870-874. (Pubitemid 350211404)
45. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40:319-326. (Pubitemid 38115839)
46. Thomas AR, Zaman A, Bell BP. Deaths from chronic liver disease and viral hepatitis, Multnomah County, Oregon, 2000. J Clin Gastroenterol 2007; 41:859-862.
47. Álvarez E. Burden of Disease atributable to HIV/AIDS in Spain using Disability Adjusted Life Year (DALY) [in Spanish]. Madrid: Universidad Rey Juan Carlos; 2006.
48. Rives J, Clèries R, Rubió A, Hernández JM, Mazzara R, Madoz P, et al. Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. Int J Cancer 2006; 119:687-694. (Pubitemid 43955725)
49. Sorensen HT, Thulstrup AM, Mellemkjar L, Jepsen P, Chrstensen E, Olsen JH, et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. J Clin Epidemiol 2003; 56:88-93. (Pubitemid 36183320)
50. Bosetti C, Fabio L, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46:877-1839
51. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368:938-945. (Pubitemid 44331386)
52. Neal KR, on behalf of the Trent Hepatitis C Study Group. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56:1098-1104.
53. De la Fuente L, Brugal MT, Domingo-Salvany A, Bravo MJ, Neira-León M, Barrio G. More than thirty years of illicit drugs in Spain: a bitter story with some messages for the future. Rev Esp Salud Pública 2006; 80:505-520.
54. Martinez-Bauer E. Prevención de la transmisión nosocomial por el VHC (Prevention of the nosocomial transmission of HCV). Gastroenterol Hepatol 2006; 29 (Suppl 2):113-116.
55. Health and Sexual Habits Survey, 2003. Madrid: National Statistics Institute (INE) 2006 [in Spanish]. http://www.ine.es/prodyser/pubweb/saludyhs03/ saludyhs03.htm.
56. Buti M, San Miguel R, Brosa M, Cabasés JM, Medina M, Casado MA, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42:639-645. (Pubitemid 40501679)
57. Idris BI, Brosa M, Richadus JH, Esteban R, Schalm SW, Buti M. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol 2008; 20:320-326.
58. Riestra S, Fernandez E, Leiva P, García S, Ocio G, Rodrigo L. Prevalence of hepatitis C virus infection in the general population of northern Spain. Eur J Gastroenterol Hepatol 2001; 13:477-481. (Pubitemid 32466247)
59. Bruguera M, Bañares R, Córdoba J, Jardi R, Gonzalez J, Ladero JM, et al. Consensus on the treatment of hepatitis B and C [in Spanish]. Gastroenterol Hepatol 2006; 29 (Suppl 2):216-230.